TICKER INTELLIGENCE
NYSE/NASDAQ: BIIB
2
Active Bills
0
Gov't Contracts
50
Congressional Trades
$BIIB is a publicly traded company in the Healthcare sector. This company operates across Healthcare and is subject to various Congressional legislative and regulatory actions. HillSignal is tracking 2 active Congressional signals mentioning $BIIB, including 2 bills. The current legislative sentiment is predominantly bullish, suggesting potential tailwinds from government policy.
⚠ ⚠️ PRESIDENTIAL ACTION: Presidential Action signed 7/20/2026: "Imposing Additional Duties to Offset Canadian Discrimination Against the Commerce of the United Stat". The 50% tariff on Canadian goods will increase costs for U.S. importers and consumers of affected products, potentially boosting domestic dairy and manufacturing sectors while straining U.S.-Canada trade relations and raising prices for consumers.
⚠ System: No suspicious timing patterns detected
⚠ System: No valid trades to analyze
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ Rob Bresnahan bought $1,001 - $15,000 in NVDA on May 12, 2025, May 13, 2025, and May 16, 2025 — 6 to 10 days before the Access Technology Affordability Act of 2025 (S1918) was introduced, a bill that could benefit the company.
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No valid trades to analyze
⚠ System: No suspicious timing patterns detected
⚠ System: No overlapping signals found
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
HR8205 reauthorizes ALS research programs through FY2031 but authorizes zero appropriated dollars. The bill is early-stage (referred to committee, no floor vote). Pure-play ALS firms like Cytokinetics are structurally most exposed, but the lack of appropriation and early legislative stage mean no near-term market impact.
The Small Biotech Innovation Act (HR3731) is an early-stage bill that would exempt R&D-intensive small biotech manufacturers (≤5 qualifying drugs) from Medicare drug price negotiations starting in 2029. The bill is in committee with no floor action, and no market reaction is evident from provided data. The legislative path is long and uncertain — this is a structural watch item, not a trading catalyst.
→ Preserves pricing flexibility for qualifying small biotech firms' single-source drugs, shielding them from mandatory price cuts
Daily AI-analyzed alerts for Congressional activity affecting your portfolio.
Get Started →